Treatment of patients with cisplatin-refractory testicular germ-cell cancer

International Journal of Cancer

Volumn 83, Issue 6, 1999, Pages 848-851

  Bokemeyer, Carsten ^a,h   Kollmannsberger, Christian ^a   Harstrick, Andreas ^b   Beyer, Jörg ^c   Gerl, Arthur ^d   Casper, Jochen ^e   Metzner, Bernd ^f   Hartmann, Jörg T ^a   Schmoll, Hans Joachim ^g   Kanz, Lothar ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY OF ROSTOCK   (Germany)

^f KLINIKUM OLDENBURG   (Germany)

^g MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^h UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IPROPLATIN; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; RETINOIC ACID; SURAMIN; TOPOTECAN;

BONE MARROW SUPPRESSION; CANCER RESISTANCE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; GERM CELL TUMOR; GRANULOCYTOPENIA; HUMAN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA;

EID: 0032709374     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(19991210)83:6<848::aid-ijc29>3.0.co;2-%23     Document Type: Conference Paper

References (22)

1. BEYER, J., BOKEMEYER, C., RICK, O., METZNER, B., CASPER, J., WANDT, H., HARTMANN, F., SCHMOLL, H.J., KANZ, L., HUHN, D. and SIEGERT, W., Salvage treatment in germ-cell tumors using taxol, ifosfamide, cisplatin (TIP) followed by high-dose carboplatin, etoposide, and thiotepa (HDCET): first results. Proc. Amer. Soc. clin. Oncol., 17, 322a (1998).
2. BEYER, J. AND 12 OTHERS, High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J. clin. Oncol., 14, 2638-2645 (1996).
3. BOKEMEYER, C., Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors. Oncology, 55, 177-188 (1998).
4. BOKEMEYER, C., BEYER, J., METZNER, B., RÜTHER, U., HARSTRICK, A., WEISSBACH, L., KÖHRMANN, U., VERBEEK, W. and SCHMOLL, H.J., Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann. Oncol., 7, 31-34 (1996).
5. BOKEMEYER, C., DROZ, J.P., HANAUSKE, A., SCHRÖDER, M., QUEISSER, W. and SCHMOLL, H.J., Treatment of relapsed nonseminoma germ cell tumors with vinorelbine: a trial of the phase I/II study group of the Association of Medical Oncology of the German Cancer Society. Onkologie, 16, 29-31 (1993).
6. BOKEMEYER, C., GERL, A., SCHÖFFSKI, P., HARSTRICK, A., NIEDERLE, N., BEYER, J., CASPER, J., SCHMOLL, H.J. and KANZ, L., Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J. clin. Oncol., 17, 512-516 (1999).
7. BOKEMEYER, C., SCHMOLL, H.J., NATT, F., KNOCHE, M., BEYER, J. and SOUCHON, R., Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplalin-refractory testicular cancer. J. Cancer Res. clin. Oncol., 120, 754-757 (1994).
8. DRASGA, R.E., WILLIAMS, S., EINHORN, L.H. and BIRCH, R., Phase II evaluation of iproplatin in refractory germ cell tumors: A Southeastern Cancer Study Group trial. Cancer Treat. Rep., 71, 863-864 (1987).
9. DUNN, T.A., SCHMOLL, H.J., GRÜNWALD, V., BOKEMEYER, C. and CASPER, J., Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell lines. Invest. New Drugs, 15, 109-114 (1997).
10. EINHORN, L.H., STENDER, M.J. and WILLIAMS, S.D., Phase II trial of gemcitabine in refractory germ cell tumors. J. clin. Oncol., 17, 509-511 (1999).
11. HARSTRICK, A., SCHMOLL, H.J., WILKE, H., SCHÖBER, C., STAHL, M., KÖHNE WÖMPNER, C., BOKEMEYER, C., DÖLKEN, G., BURK, K. and POLIWODA, H., High dose epirubicin in refractory or relapsed non-seminomatous testicular cancer: a phase II study. Ann. Oncol., 1, 375-376 (1990).
12. HOSKINS, P., COPPIN, C.M. and MURRAY, N., Mitomycin is active against refractory germ-cell tumors. A phase II study. Amer. J. clin. Oncol., 13, 35-38 (1990).
13. MOASSER, M.M., MOTZER, R.J., KHOO, K.S., LYN, P., MURPHY, B., BOSL, G.J. and DMITROVSKY, E., All-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. Cancer, 76, 680-686 (1995).
14. MOTZER, R.J., BAJORIN, D., SCHWARTZ, L.H., HUTTER, H.S., BOSL, G.J., SCHER, H., LYN, P. and FISCHER, P., Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J. clin. Oncol., 12, 2277-2283 (1994).
15. MOTZER, R.J., DMITROVSKY, E., MILLER, W.H.J., TONG, W.P., BAJORIN, D., SCHER, H. and BOSL, G.J., Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. Cancer, 72, 3313-3317 (1993).
16. MURPHY, B., MOTZER. R.J. and BOSL, G.J., Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT. Invest. New Drugs, 10, 327-330 (1992).
17. NASARIO, A., AMATO, R.J., HUTCHINSON, L., BUI, C., ELLERHORST, J. and LOGOTHETIS, C., Paclitaxel in extensively pretreated nonseminomatous germ cell tumors. Urol. Oncol., 1, 184-187 (1995).
18. PONT, J., BOKEMEYER, C., HARSTRICK, A., SELLNER, F., GREINIX, H. and STOIBER, F., Chemotherapy for germ cell tumors relapsing after high-dose chemotherapy and stem cell support: a retrospective multicenter study of the Austrian Study Group on Urologie Oncology. Ann. Oncol., 8, 1229-1234 (1997).
19. PUC, H.S., BAJORIN, D., BOSL, G.J., AMSTERDAM, A. and MOTZER, R.J., Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. Invest. New Drugs, 13, 163-165 (1995).
20. SANDLER, A.B., CRISTOU, A., Fox, S., WILLIAMS, S.D., NICHOLS, C.R., TURNS, M. and RSCROTH, B.J., A phase II trial of paclitaxel in refractory germ cell tumors. Cancer, 82, 1381-1386 (1998).
21. STOTER, G., AKDAS, A., FOSSÅ, S.D., KAYE, S.B., VAN GROENINGEN, C.J., RENARD, J. and VAN GLABBEKE, M., High-dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer: a phase II study. Ann. Oncol., 3, 577-578 (1992).
22. WILLIAMS, S.D., BIRCH, R., GAMS, R. and IRWIN, L., Phase II trial of mitoxantrone in refractory germ cell tumors: a trial of the Southeastern Cancer Study Group. Cancer Treat. Rep., 69, 1455-1456 (1985).